MAPT and Alzheimer disease: The 2024 AA workgroup criteria propose that an abnormality in one of the specific core 1 biomarkers (or a combination of them) is sufficient for the diagnosis of AD: amyloid PET, CSF Aβ42/40, CSF p-tau 181/Aβ42, or CSF t-tau/Aβ42 (Table 2).